Compounds > niacinamide

niacinamide and carboplatin

niacinamide has been researched along with carboplatin in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (10.00)29.6817
2010's27 (90.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albertini, MR; Brose, MS; Elder, D; Flaherty, KT; Hingorani, SR; Jacobetz, MA; Lathia, C; Liu, G; O'Dwyer, PJ; Petrenciuc, O; Redlinger, M; Schiller, J; Schuchter, LM; Tuveson, DA; Van Belle, PA; Weber, BL; Xia, C1
Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM1
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C1
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S1
Blumenschein, GR; Gladish, G; McGreivy, J; O'Rourke, T; Parson, M; Reckamp, K; Sandler, A; Stephenson, GJ; Sun, YN; Ye, Y1
Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M1
Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J1
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM1
Beck, JT; Blumenschein, GR; Hei, YJ; Kabbinavar, F; Kracht, K; Lakshmaiah, K; Menon, H; Mok, TSK; Reckamp, K; Schwartzberg, L; Sikorski, R; Stephenson, J; Sun, YN1
Banaclocha, NM; Blackhall, F; Ciuleanu, TE; Dediu, M; Galimi, F; Galiulin, R; Hei, YJ; Ichinose, Y; Kubota, K; McCoy, S; Papai-Szekely, Z; Park, K; Pirker, R; Scagliotti, GV; Spigel, DR; Sydorenko, O; Vynnychenko, I; Yao, B1
Bruno, R; Claret, L; Hei, YJ; Hsu, CP; Lu, JF; Sun, YN1
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS1
Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F1
Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A1
He, ZY; Hua, XD1
D'Andrea, K; Flaherty, KT; Jilaveanu, LB; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Wilson, M; Zhao, F; Zito, CR1
Hei, YJ; Hsia, TC; Ichinose, Y; Kim, JH; Kim, SW; Kubota, K; Li, RK; Lim, WT; Park, K; Scagliotti, G; Shinkai, T; Spigel, D; Takeda, K; Tiangco, BJ; Yao, B; Yau, S1
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ1
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F1
Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A; Vanni, I1
Blackhall, F; Hei, YJ; McCoy, S; Novello, S; Scagliotti, GV; Schneider, CP; Spigel, DR; Sydorenko, O; Volovat, C; Vynnychenko, I1
Bass, MB; Chan, SS; Davis, GJ; Davis, MT; Hei, YJ; Kaesdorf, BA; Patterson, SD; Yao, B; Ye, Y1
Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC1
Gavrancic, T; Park, YH1
D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F1
Booth, L; Carter, J; Dent, P; McGuire, WP; Poklepovic, A; Roberts, JL; Webb, T1
Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME1
Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J1
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC1
Asato, T; Cho, EK; Hara, K; Hayashi, H; Hida, T; Ichinose, Y; Kaneda, H; Kato, T; Kubota, K; Lee, KH; Lin, CB; Nakagawa, K; Oshita, F; Park, K; Tanaka, H; Yamada, K; Yang, JC; Yoh, K; Yoshioka, H1

Reviews

2 review(s) available for niacinamide and carboplatin

ArticleYear
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases

2014
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
    World journal of urology, 2017, Volume: 35, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms

2017

Trials

23 trial(s) available for niacinamide and carboplatin

ArticleYear
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biopsy; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome

2008
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome

2009
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Radiography; Sorafenib; Treatment Outcome

2010
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Panitumumab; Receptors, Vascular Endothelial Growth Factor

2010
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib

2010
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2010
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate

2011
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-10, Volume: 30, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Young Adult

2012
Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
    Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Humans; Indoles; Lung Neoplasms; Models, Biological; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Survival Rate

2012
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms

2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2013
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Clinical lung cancer, 2013, Volume: 14, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed

2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2013
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Treatment Outcome; Young Adult

2014
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib

2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate

2014
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Hemoptysis; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate

2014
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Placebo Effect; Placenta Growth Factor; Pregnancy Proteins; Proportional Hazards Models; ROC Curve; Survival Rate

2014
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
    Cancer medicine, 2015, Volume: 4, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome

2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome

2016
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Hepatitis C; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib

2016
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Nov-10, Volume: 35, Issue:32

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Hong Kong; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Republic of Korea; Survival Rate; Treatment Outcome

2017

Other Studies

5 other study(ies) available for niacinamide and carboplatin

ArticleYear
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
    Cancer control : journal of the Moffitt Cancer Center, 2009, Volume: 16, Issue:1

    Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes

2009
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Iodized Oil; Liver Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate

2012
A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2015
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
    Cancer biology & therapy, 2015, Volume: 16, Issue:11

    Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Inhibitory Concentration 50; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Phenylurea Compounds; Sildenafil Citrate; Sorafenib

2015
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult

2017